Treatment of mucopolysaccharidosis type II (Hunter syndrome): results from a systematic evidence review.

about

Advances in computer-assisted syndrome recognition by the example of inborn errors of metabolism.Targeting Root Cause by Systemic scAAV9-h Gene Delivery: Functional Correction and Reversal of Severe MPS II in Mice

P2860

Q52805801-2350A355-025C-4E9D-9159-D28D5A2115F9 Q58765137-8A499BB3-4ED5-4E7B-B3F2-3B18D8913D9A

P2860

Treatment of mucopolysaccharidosis type II (Hunter syndrome): results from a systematic evidence review.

Item

http://www.wikidata.org/entity/Q38714026

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Treatment of mucopolysaccharid ...... a systematic evidence review.

@en

type

Item

label

Treatment of mucopolysaccharid ...... a systematic evidence review.

@en

prefLabel

Treatment of mucopolysaccharid ...... a systematic evidence review.

@en

P1476

Treatment of mucopolysaccharid ...... a systematic evidence review.

@en

P2093

Glenn E Palomaki

http://www.w3.org/2001/XMLSchema#string

Hamish R M Haddow

http://www.w3.org/2001/XMLSchema#string

Linda A Bradley

http://www.w3.org/2001/XMLSchema#string

P2860

A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)

Incidence of Hunter's syndrome

Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II).

Home treatment with intravenous enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II - data from the Hunter Outcome Survey.

A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4-7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy.

Impact of Enzyme Replacement Therapy and Hematopoietic Stem Cell Therapy on Growth in Patients with Hunter Syndrome.

Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series.

Clinical efficacy of enzyme replacement therapy in paediatric Hunter patients, an independent study of 3.5 years.

The effect of idursulfase on growth in patients with Hunter syndrome: data from the Hunter Outcome Survey (HOS).

Activities of daily living in patients with Hunter syndrome: impact of enzyme replacement therapy and hematopoietic stem cell transplantation.

P2888

gim.2017.30

P31

scholarly article

P356

10.1038/GIM.2017.30

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2017-06-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28640238

http://www.w3.org/2001/XMLSchema#string

Treatment of mucopolysaccharidosis type II (Hunter syndrome): results from a systematic evidence review.

about

P2860

P2860

Treatment of mucopolysaccharidosis type II (Hunter syndrome): results from a systematic evidence review.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P31

P356

P407

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P31

P356

P407

P577

P698